By using our site you accept the terms of our cookie policy


4D Pharma Plc

August 1, 2019

4D Pharma Plc

Best Live Biotherapeutics Development Company 2019 - UK & Best Proprietary Discovery Platform: MicroRx®

4D develops Live Biotherapeutics, a novel and emerging class of drugs. 4D’s highly productive discovery platform, MicroRx®, selects bacterial isolates with a therapeutic effect in diseases by identifying strains having significant effects on the host and targeting diseases driven by pathways that match this profile of the strain. 4D has four clinical studies in progress - a Phase II study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I monotherapy study of MRx0518 in patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma.

Contact Us

+44 (0) 203 725 6847